NRX Debt Ratio from 2010 to 2024

NRXP Stock  USD 1.31  0.02  1.55%   
NRX Pharmaceuticals Debt Ratio yearly trend continues to be relatively stable with very little volatility. Debt Ratio is likely to grow to 1.31 this year. During the period from 2010 to 2024, NRX Pharmaceuticals Debt Ratio destribution of quarterly values had range of 1.3003 from its regression line and mean deviation of  0.31. View All Fundamentals
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
1.25235817
Current Value
1.31
Quarterly Volatility
0.44367187
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 114 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Latest NRX Pharmaceuticals' Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of NRX Pharmaceuticals over the last few years. It is NRX Pharmaceuticals' Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Debt Ratio10 Years Trend
Slightly volatile
   Debt Ratio   
       Timeline  

NRX Debt Ratio Regression Statistics

Arithmetic Mean0.23
Geometric Mean0.03
Coefficient Of Variation195.42
Mean Deviation0.31
Median0.01
Standard Deviation0.44
Sample Variance0.20
Range1.3003
R-Value0.70
Mean Square Error0.11
R-Squared0.49
Significance0
Slope0.07
Total Sum of Squares2.76

NRX Debt Ratio History

2024 1.31
2023 1.25
2022 0.41
2021 0.0158
2020 0.27
2019 0.0609

Other Fundumenentals of NRX Pharmaceuticals

NRX Pharmaceuticals Debt Ratio component correlations

0.980.080.83-0.880.970.91-0.84-0.490.97-0.94-0.010.7-0.62-0.64-0.71-0.58-0.640.58
0.980.090.79-0.870.940.91-0.92-0.460.94-0.920.120.63-0.57-0.59-0.64-0.53-0.590.51
0.080.090.27-0.330.310.38-0.11-0.820.31-0.33-0.40.4-0.590.08-0.08-0.690.08-0.33
0.830.790.27-0.880.90.91-0.61-0.740.89-0.88-0.450.96-0.91-0.85-0.93-0.86-0.850.66
-0.88-0.87-0.33-0.88-0.91-0.960.760.64-0.90.940.2-0.80.750.660.80.730.66-0.47
0.970.940.310.9-0.910.96-0.79-0.71.0-0.98-0.180.81-0.79-0.66-0.75-0.76-0.660.5
0.910.910.380.91-0.960.96-0.83-0.730.96-0.98-0.160.82-0.81-0.7-0.78-0.79-0.70.41
-0.84-0.92-0.11-0.610.76-0.79-0.830.35-0.790.77-0.41-0.410.380.40.410.360.4-0.27
-0.49-0.46-0.82-0.740.64-0.7-0.730.35-0.70.690.58-0.830.940.450.570.970.45-0.15
0.970.940.310.89-0.91.00.96-0.79-0.7-0.98-0.180.81-0.78-0.65-0.74-0.75-0.650.49
-0.94-0.92-0.33-0.880.94-0.98-0.980.770.69-0.980.2-0.810.790.70.780.760.7-0.42
-0.010.12-0.4-0.450.2-0.18-0.16-0.410.58-0.180.2-0.660.670.420.550.670.42-0.33
0.70.630.40.96-0.80.810.82-0.41-0.830.81-0.81-0.66-0.97-0.81-0.92-0.94-0.810.61
-0.62-0.57-0.59-0.910.75-0.79-0.810.380.94-0.780.790.67-0.970.710.810.990.71-0.42
-0.64-0.590.08-0.850.66-0.66-0.70.40.45-0.650.70.42-0.810.710.930.631.0-0.59
-0.71-0.64-0.08-0.930.8-0.75-0.780.410.57-0.740.780.55-0.920.810.930.750.93-0.7
-0.58-0.53-0.69-0.860.73-0.76-0.790.360.97-0.750.760.67-0.940.990.630.750.63-0.33
-0.64-0.590.08-0.850.66-0.66-0.70.40.45-0.650.70.42-0.810.711.00.930.63-0.59
0.580.51-0.330.66-0.470.50.41-0.27-0.150.49-0.42-0.330.61-0.42-0.59-0.7-0.33-0.59
Click cells to compare fundamentals

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Debt Ratio, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Debt Ratio 1.25  1.31 
Cash Flow To Debt Ratio(2.36)(2.48)

Pair Trading with NRX Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with NRX Stock

  0.77ME 23Andme Holding Upward RallyPairCorr
  0.74VALN Valneva SE ADRPairCorr

Moving against NRX Stock

  0.84DRUG Bright Minds Biosciences TrendingPairCorr
  0.64SABSW SAB BiotherapeuticsPairCorr
  0.59VCYT VeracytePairCorr
  0.56VERA Vera TherapeuticsPairCorr
  0.46DSGN Design TherapeuticsPairCorr
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.